![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
RP Shank, JL Vaught, KA Pelley, PE Setler, DF McComsey and BE Maryanoff
Department of Biological Research, McNeil Pharmaceutical, Spring House, Pennsylvania.
McN-5652 is one of a series of substituted pyrrolo-isoquinolines that, as a group, potently inhibit the uptake of one or more of the monoamines, norepinephrine, serotonin and dopamine. McN-5652 is characterized by exceptionally high potency as an inhibitor of the uptake of serotonin by rat brain synaptosomes in vitro (Ki approximately 0.6 nM) and ex vivo (ED50 approximately 2 mg/kg p.o.). The high potency of McN-5652 as a serotonin uptake inhibitor in vivo is indicated further by the low doses required to potentiate L-5- hydroxytryptophan-induced head twitches in mice (ED50 = 0.4 mg/kg 2 hr after p.o. dosing) and the serotonin syndrome in rats (ED50 = 1.5 mg/kg 2 hr after p.o. dosing). McN-5652 also potently inhibited the synaptosomal uptake of norepinephrine (Ki approximately 3 nM) and was a moderately potent inhibitor of the synaptosomal uptake of dopamine (Ki approximately 40 nM). McN-5652 inhibited tetrabenazine-induced ptosis in rats and mice but was much less effective in blocking the sedation caused by tetrabenazine. In rats, McN-5652 did not induce the stereotyped behavior often caused by dopamine agonists and inhibitors of dopamine uptake. Receptor binding experiments indicated that McN- 5652 has a weak affinity for serotonin 5-HT2 and alpha-1 adrenergic receptors (apparent Ki approximately 200 nM) and a very low affinity for dopamine D1 and D2 receptors, serotonin 5-HT1, alpha-2 adrenergic, muscarinic and gamma-aminobutyric acid-A receptors. Experiments using the guinea pig ileum indicate that McN-5652 is a weak, noncompetitive antagonist of histamine.
This article has been cited by other articles:
|
|
 |
|
  R. Buchert, R. Thomasius, F. Wilke, K. Petersen, B. Nebeling, J. Obrocki, O. Schulze, U. Schmidt, and M. Clausen A Voxel-Based PET Investigation of the Long-Term Effects of "Ecstasy" Consumption on Brain Serotonin Transporters Am J Psychiatry, July 1, 2004; 161(7): 1181 - 1189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Suhara, A. Takano, Y. Sudo, T. Ichimiya, M. Inoue, F. Yasuno, Y. Ikoma, and Y. Okubo High Levels of Serotonin Transporter Occupancy With Low-Dose Clomipramine in Comparative Occupancy Study With Fluvoxamine Using Positron Emission Tomography Arch Gen Psychiatry, April 1, 2003; 60(4): 386 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Buchert, R. Thomasius, B. Nebeling, K. Petersen, J. Obrocki, L. Jenicke, F. Wilke, L. Wartberg, P. Zapletalova, and M. Clausen Long-Term Effects of "Ecstasy" Use on Serotonin Transporters of the Brain Investigated by PET J. Nucl. Med., March 1, 2003; 44(3): 375 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pineyro and P. Blier Autoregulation of Serotonin Neurons: Role in Antidepressant Drug Action Pharmacol. Rev., September 1, 1999; 51(3): 533 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Goodnick and B. J. Goldstein Selective serotonin reuptake inhibitors in affective disorders -- I. Basic pharmacology J Psychopharmacol, January 1, 1998; 12(4_suppl): 5 - S20. [Abstract] [PDF]
|
|
|
|
|
|
R. Lane, D. Baldwin, and S. Preskorn The SSRIs: advantages, disadvantages and differences J Psychopharmacol, January 1, 1995; 9(2_suppl): 163 - 178. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
